pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,712 stories · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT959Endpoints733BioPharma Dive280BioSpace178Fierce Biotech168onclive165globenewswire health73raps62fda recalls
therapy area
allOncology5576Rare Disease1221Cardiology1044Hematology919Immunology909Vaccines796Pulmonology772Psychiatry & CNS687
  • Trump plans to fire Makary from FDA role, according to reports
    FDA Commissioner Marty Makary is expected to be fired from his role, according to multiple media reports. The plans haven’t been finalized and could still change, said the Wall Street Journal ...
    Endpoints · 3mo ago↗ source
  • FDA Commissioner Makary to be fired, WSJ reports
    President Donald Trump is planning to fire FDA Commissioner Marty Makary, the Wall Street Journal reported on Friday. The plans haven't been finalized and could still change, the Journal said. Repr…
    Endpoints · 3mo ago↗ source
  • Daiichi Sankyo posts 'extraordinary loss' of nearly $1B
    Daiichi Sankyo is scrapping plans to build antibody-drug conjugate manufacturing capacity and recorded an "extraordinary loss" of 149.4 billion Japanese yen ($950 million) after overpromising deman…
    Endpoints
← prev
page 93 of 109
next →
40
fda medwatch29
fda press25
Ophthalmology341
Endocrinology & Metabolism336
Pain330
Infectious Disease321
· 3mo ago
↗ source
  • UT MD Anderson Shares Latest Research Breakthroughs
    The University of Texas MD Anderson Cancer Center released recent oncology research highlights.
    onclive · 3mo ago↗ source
  • Opinion: I’m fighting misinformation online. False hantavirus claims follow a now-familiar playbook
    The cruise ship hantavirus outbreak is serious but limited. Online, it's another story.
    STAT · 3mo ago↗ source
  • Lilly to invest extra $4.5B across Indiana manufacturing
    The Indianapolis-based company expanded its spend to ensure it can meet growing demand for its weight-loss drugs.
    BioPharma Dive · 3mo ago↗ source
  • Giants of Cancer Care Announces the 14th Annual Class of Inductees
    onclive · 3mo ago↗ source
  • OncLive Weekly News Quiz (5/8/2026): Test Your Knowledge on Key Breast, Lung, and Pancreatic Cancer Updates
    Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
    onclive · 3mo ago↗ source
  • Former FDA leaders, pharma speak out on mifepristone
    “The fundamental question is: Who gets to regulate mifepristone?”
    STAT · 3mo ago↗ source
  • FDA delays Leqembi decision; Artiva raises $300M; Pharvaris prices offering
    🗓️ FDA delays subcutaneous Leqembi decision: Originally slated for later this month, the decision date now falls on August 24, Biogen and Eisai said. The agency asked for more information from ...
    Endpoints · 3mo ago↗ source
  • STAT+: Up and down the ladder: The latest comings and goings
    From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
    STAT · 3mo ago↗ source
  • The biotechs wear Prada
    Was Naomi Osaka's Met Gala outfit inspired by Gilead's logo? Janelle Monáe's by Insilico's? Probably not — and yet.
    STAT · 3mo ago↗ source
  • OncLive Polls Reveal Picks for Top Lung Cancer Abstracts at ASCO 2026
    Lung cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.
    onclive · 3mo ago↗ source
  • Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026
    Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ASCO 2026.
    onclive · 3mo ago↗ source
  • FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extended
    Pierre Fabre claims to now be “aligned” with U.S. regulators on the path forward for a twice-rejected treatment. Elsewhere, Argenx swapped CEOs and Blackstone made a $250 million biotech investment.
    BioPharma Dive · 3mo ago↗ source
  • STAT+: The biotech news you need to read today
    A Duchenne therapy lawsuit, FDA Commissioner Marty Makary’s White House troubles, and other news from The Readout
    STAT · 3mo ago↗ source
  • Lilly, Gilead lead pharma’s M&A boom
    Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune disease drugs.
    BioPharma Dive · 3mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about an FDA gender rule change, its program for one-day inspections, and more
    An FDA proposal to remove references to “gender” from its regulations sparked concerns about unintended consequences on research
    STAT · 3mo ago↗ source
  • 'Pharma, not really’: Top young AI talent shuns careers at big drugmakers
    RIO DE JANEIRO — Mazdak Abulnaga should be the poster child for the type of employee pharma companies want to hire this year. Abulnaga, a 33-year-old postdoctoral fellow at MIT and Harvard Medical…
    Endpoints · 3mo ago↗ source
  • Dr Gruenbaum on Where Alternative Options to BTK Inhibitors Stand in MCL
    Lore Gruenbaum, PhD, discusses alternative treatments to BTK inhibitors like bispecific antibodies and CAR T-cell therapy in mantle cell lymphoma.
    onclive · 3mo ago↗ source
  • The PYNNACLE Phase 2 trial assessing rezatapopt, a selective p53 reactivator, in patients with advanced or metastatic solid tumors harboring a TP53 Y220C mutation: Interim analysis of patients with ovarian cancer
    Alison Schram, MD, discusses interim PYNNACLE phase 2 data showing that single-agent rezatapopt produced clinically meaningful responses and a manageable safety profile in heavily pretreated patien…
    onclive · 3mo ago↗ source
  • Characterization and Management of Sevabertinib induced Diarrhea in the SOHO 1 study
    This analysis from the SOHO-01 study evaluated the safety profile of sevabertinib in HER2-mutated non–small cell lung cancer, with a specific focus on treatment-related diarrhea. Diarrhea was frequ…
    onclive · 3mo ago↗ source
  • First-Line Danvatirsen Plus Pembrolizumab Fails to Improve Response Rates in Metastatic HNSCC
    Danvatirsen in combination with pembrolizumab did not result in an ORR improvement vs pembrolizumab alone in first-line recurrent/metastatic HNSCC.
    onclive · 3mo ago↗ source
  • Cumulative ADC Toxicities and Closing Reflections: Managing Edema, Fatigue, and Optimizing Long-Term Tolerability
    This concluding segment addresses cumulative toxicities affecting long-term antibody-drug conjugate tolerability, with Hope Rugo, MD and Aaron Lisberg, MD discussing edema, fatigue, and strategies…
    onclive · 3mo ago↗ source
  • The aging scientific workforce collides with rising fabricating citations in medical journals
    The latest in the hantavirus cruise ship saga, why these former officials left the FDA, and more health news from Morning Rounds
    STAT · 3mo ago↗ source